Virginia Retirement Systems ET AL Has $1.63 Million Position in Catalent Inc (CTLT)
Virginia Retirement Systems ET AL increased its position in shares of Catalent Inc (NYSE:CTLT) by 83.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 39,000 shares of the company’s stock after purchasing an additional 17,700 shares during the quarter. Virginia Retirement Systems ET AL’s holdings in Catalent were worth $1,634,000 as of its most recent SEC filing.
A number of other institutional investors have also recently added to or reduced their stakes in the stock. Mason Street Advisors LLC boosted its holdings in Catalent by 2.3% during the first quarter. Mason Street Advisors LLC now owns 66,961 shares of the company’s stock worth $2,749,000 after purchasing an additional 1,505 shares during the last quarter. Municipal Employees Retirement System of Michigan raised its position in Catalent by 4.3% in the first quarter. Municipal Employees Retirement System of Michigan now owns 41,420 shares of the company’s stock worth $1,701,000 after acquiring an additional 1,690 shares during the period. Atria Investments LLC raised its position in Catalent by 26.2% in the second quarter. Atria Investments LLC now owns 9,064 shares of the company’s stock worth $380,000 after acquiring an additional 1,881 shares during the period. Allianz Asset Management GmbH raised its position in Catalent by 0.3% in the first quarter. Allianz Asset Management GmbH now owns 710,919 shares of the company’s stock worth $29,190,000 after acquiring an additional 2,021 shares during the period. Finally, Massachusetts Financial Services Co. MA raised its position in Catalent by 15.9% in the second quarter. Massachusetts Financial Services Co. MA now owns 15,152 shares of the company’s stock worth $635,000 after acquiring an additional 2,075 shares during the period. Institutional investors and hedge funds own 99.07% of the company’s stock.
In other news, SVP Steven L. Fasman sold 2,252 shares of the business’s stock in a transaction that occurred on Wednesday, June 20th. The shares were sold at an average price of $41.78, for a total value of $94,088.56. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 1.70% of the company’s stock.
Several analysts have commented on the stock. Zacks Investment Research raised shares of Catalent from a “hold” rating to a “buy” rating and set a $48.00 price objective on the stock in a research report on Monday, July 9th. ValuEngine raised shares of Catalent from a “hold” rating to a “buy” rating in a research report on Tuesday, June 26th. Six research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Catalent currently has an average rating of “Buy” and a consensus price target of $46.00.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through three segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. The Softgel Technologies segment offers formulation, development, and manufacturing services for softgels, which are used in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, and unit-dose cosmetics.
Further Reading: What does earnings per share mean?
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.